Now, as the biotech plugs away at a phase 2a study, it's reporting new data showing the drug's effects lasting as far out as 21 months. Last April, the ...
News
- Frequency's hearing loss treatment shows long-term promise
- Big pharma's safety pledge isn't enough to build public confidence in COVID-19 vaccine – here's ...
Nevertheless, biotech firms have every incentive to be the first to bring a coronavirus vaccine to market, even if it means cutting a corner or two. The ...
- EU presses China on market access, human rights
Xi did not take part in the post-summit news conference. Citing a lack of opportunities in China's communications, IT, biotech and health care sectors, ...
- 'We're in trouble right now,': Chamber of Commerce CEO says on SA's coronavirus-stricken economy
President and CEO of the San Antonio Chamber of Commerce Richard ... care and biosciences industry and, of course, the cybersecurity industry.
- Frequency Therapeutics Presents Results Demonstrating Sustained Improvement in Hearing Loss ...
BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate ... King, co-founder of the Ear Medical Group in San Antonio and Clinical Professor, ...